PMID- 29151113
OWN - NLM
STAT- MEDLINE
DCOM- 20180713
LR  - 20190606
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 23
DP  - 2017 Nov 19
TI  - CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF 
      Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer.
PG  - 5504-5514
AB  - BACKGROUND CPNE1 plays a vital role in regulating cell differentiation. The 
      clinical and biological values of CPNE1 in prostate cancer are still unclear. The 
      aim of this study was to investigate the clinicopathological value of CPNE1 and 
      the association of CPNE1 with TRAF2 expression in patients with prostate cancer. 
      MATERIAL AND METHODS CPNE1 expression in prostate cancer was analyzed using Gene 
      Expression Omnibus (GEO) databases. The Cancer Genome Atlas (TCGA) dataset was 
      used to investigate the association of CPNE1 expression with TRAF2 expression in 
      prostate cancer. The association of CPNE1 expression with recurrence-free 
      survival in patients was also analyzed using the TCGA dataset. 
      Immunohistochemistry assay was performed to examine CPNE1 expression in 65 normal 
      prostate samples and 114 prostate cancer samples. The recurrence-free survival in 
      patients was evaluated using Kaplan-Meier curves and log-rank test. In addition, 
      multivariate and univariate analyses of prognostic factors were investigated by 
      Cox regression. The effect of CPNE1 on TRAF2 expression was explored in human 
      prostate cancer DU-145 cells. RESULTS Our results showed that expression level of 
      CPNE1 is higher in prostate cancer than in normal prostate tissues (P=0.006). In 
      the GSE35988 dataset, CPNE1 expression was found to be upregulated in 
      castration-resistant prostate cancer compared with non-castration-resistant 
      prostate cancer (P<0.001). Furthermore, we found that CPNE1 high expression was 
      significantly related to tumor stage, Gleason score, and poorer biochemical 
      recurrence-free survival in prostate cancer patients. Co-expression analysis of 
      TCGA data showed that CPNE1 is significantly associated with TRAF2 expression. 
      CPNE1 overexpression can upregulate TRAF2 expression in prostate cancer DU-145 
      cells as determined by Western blotting and immunofluorescence assays. 
      CONCLUSIONS Overall, our findings suggest that CPNE1 is a valuable prognostic 
      marker for evaluating recurrence-free survival and is positively related to TRAF2 
      expression in prostate cancer.
FAU - Liang, Jiabei
AU  - Liang J
AD  - Department of Pathology, Affiliated Wuxi People's Hospital, Nanjing Medical 
      University, Wuxi, Jiangsu, China (mainland).
FAU - Zhang, Jian
AU  - Zhang J
AD  - Department of Urology, Affiliated Wuxi People's Hospital, Nanjing Medical 
      University, Wuxi, Jiangsu, China (mainland).
FAU - Ruan, Jun
AU  - Ruan J
AD  - Department of Urology, Affiliated Wuxi People's Hospital, Nanjing Medical 
      University, Wuxi, Jiangsu, China (mainland).
FAU - Mi, Yuanyuan
AU  - Mi Y
AD  - Department of Urology, The Third Affiliated Hospital of Nantong University, Wuxi, 
      Jiangsu, China (mainland).
FAU - Hu, Qiang
AU  - Hu Q
AD  - Department of Urology, Affiliated Wuxi People's Hospital, Nanjing Medical 
      University, Wuxi, Jiangsu, China (mainland).
FAU - Wang, Zhirong
AU  - Wang Z
AD  - Department of Urology, Affiliated Wuxi People's Hospital, Nanjing Medical 
      University, Wuxi, Jiangsu, China (mainland).
FAU - Wei, Bingbing
AU  - Wei B
AD  - Department of Urology, Affiliated Wuxi People's Hospital, Nanjing Medical 
      University, Wuxi, Jiangsu, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20171119
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CPNE1 protein, human)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (PSMD2 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (TNF Receptor-Associated Factor 2)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*biosynthesis/genetics
MH  - Calcium-Binding Proteins/*biosynthesis/genetics
MH  - Cell Line, Tumor
MH  - Databases, Genetic
MH  - HEK293 Cells
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prostatic Neoplasms/genetics/*metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - TNF Receptor-Associated Factor 2/*biosynthesis/genetics
MH  - Up-Regulation
PMC - PMC5704508
COIS- Conflicts of interest None.
EDAT- 2017/11/21 06:00
MHDA- 2018/07/14 06:00
PMCR- 2017/11/19
CRDT- 2017/11/20 06:00
PHST- 2017/11/20 06:00 [entrez]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2018/07/14 06:00 [medline]
PHST- 2017/11/19 00:00 [pmc-release]
AID - 904720 [pii]
AID - 10.12659/msm.904720 [doi]
PST - epublish
SO  - Med Sci Monit. 2017 Nov 19;23:5504-5514. doi: 10.12659/msm.904720.